Bionano Genomics, Inc. - BNGO STOCK NEWS

Bionano Genomics (Nasdaq: BNGO) announced the issuance of US Patent No. 10,995,364 on May 4, 2021, covering methods for single-molecule whole genome analysis. This patent enhances DNA molecule labeling using sequence-specific probes, improving detection of disease-causing variants and single-basepair changes. The patented methods bolster the Saphyr® System's capabilities, which already excel in structural variant detection. CEO Erik Holmlin emphasized the patent's role in strengthening Bionano's intellectual property portfolio, comprising 67 patents across 14 families, aiding in detailed genomic analysis for cancer and genetic diseases.

Bionano Genomics (BNGO) announced that the Georgia Esoteric and Molecular (GEM) Laboratory at Augusta University is now offering diagnostic services for genetic disorders using optical genome mapping (OGM) with the Saphyr® System. Developed by Dr. Ravindra Kolhe, this laboratory-developed test (LDT) targets pediatric patients suspected of neurodevelopmental disorders. The OGM-based LDT aims to streamline traditional testing workflows, reduce costs, and improve diagnostic rates by combining multiple testing functions into a single assay.

Bionano Genomics (Nasdaq: BNGO) announced the publication of a transformative study on DNA replication mechanisms, enhancing cancer research capabilities. Conducted by Dr. Nicholas Rhind and an international team, the study utilized the Saphyr system, which demonstrated a remarkable ability to analyze DNA replication timing, speed, and origin at a coverage level thousands of times greater than previous methods. This breakthrough could pave the way for new cancer drug development with fewer side effects, positioning Saphyr as a pivotal tool in genomic research.

Bionano Genomics (BNGO) has announced the adoption of its Saphyr system for optical genome mapping (OGM) by two major UK National Health Service (NHS) laboratories: King’s College Hospital and the NHS Regional Genetics Laboratory in Belfast. These institutions will use Saphyr to assess genomes of patients with hematological malignancies, among other genetic diseases. CEO Erik Holmlin emphasized that this shift towards OGM represents a modernization of cytogenetic workflows, potentially accelerating data generation and enhancing patient care outcomes.

Bionano Genomics announced a new IRB-approved preclinical evaluation study using optical genome mapping (OGM) in partnership with the Foundation for Embryonic Competence (FEC) to improve IVF outcomes. The study will analyze genomes of couples with recurrent pregnancy loss or implantation failure to identify structural rearrangements that traditional methods may miss. OGM's high resolution aims to enhance preimplantation testing, potentially leading to healthier pregnancies. CEO Erik Holmlin emphasized the growth of OGM applications to support couples facing genetic challenges.

Bionano Genomics announced its largest presence at the 2021 ACMG Annual Meeting, showcasing 16 presentations related to its technology across key genetic markets. The event, held virtually from April 13-16, 2021, highlighted advancements in prenatal, postnatal, blood cancers, and solid tumors. CEO Erik Holmlin expressed pride in the extensive representation of Bionano data, emphasizing its growing significance in the medical genetics community and potential to overcome barriers in the US market.

Bionano Genomics (BNGO) announced that it will present multiple studies on structural variant detection using its optical genome mapping technology at the American Association for Cancer Research (AACR) Annual Meeting 2021. The event will take place virtually from April 10-15, 2021. Notable presentations include a Spotlight Presentation highlighting the technology's application in cancer research and a study discussing drug sensitivities in leukemias. Bionano's Saphyr system supports genetic research and diagnostic testing for neurodevelopmental disorders.

Bionano Genomics has announced the adoption of the Saphyr system for optical genome mapping by Indalo Bio in South Africa, representing the first use of this technology on the continent. Indalo Bio aims to develop assays for analyzing cancer genomes in patients with hematological malignancies and solid tumors. Jo-Ann Kotze, Head of Genetics at Indalo Bio, expressed confidence in OGM's potential to enhance cytogenetic analysis. CEO Erik Holmlin emphasized the importance of expanding access to advanced genetic technologies, particularly in Africa, which could improve patient outcomes globally.

Bionano Genomics (BNGO) recently published a study in the journal Genes detailing the effectiveness of optical genome mapping (OGM) in prenatal genetic testing. The study highlights OGM's capacity to detect all types of structural variants (SVs), positioning it as a potential new standard in prenatal analysis. Notable findings include the identification of genetic disorders like trisomy 21 and DiGeorge syndrome. The research emphasizes OGM's cost-effectiveness and quick turnaround time, suggesting it could enhance prenatal testing workflows significantly.